134
Participants
Start Date
February 20, 2024
Primary Completion Date
December 30, 2026
Study Completion Date
December 30, 2028
albumin paclitaxel, cispatin, tislelizumab
Neoadjuvant immunochemotherapy (2 cycles, and 21 days each cycle, 260mg/m2 albumin paclitaxel intravenously on day 1 and day 22, with 75mg/m2 of cisplatin and 200mg of tislelizumab) + radical surgery + adjuvant therapy (radiation/chemoradiation followed by 200mg of tislelizumab, every 3 weeks for one year)
RECRUITING
Huashan Hospital, Fudan University, Shanghai
Sun Yat-sen University
OTHER
Fudan University
OTHER
Central South University
OTHER
Fujian Medical University
OTHER
Lai-ping Zhong
OTHER